Pharming Group (OTCMKTS:PHGUF – Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported $0.01 EPS for the quarter, reports. The firm had revenue of $106.50 million for the quarter, compared to analyst estimates of $89.72 million. Pharming Group had a return on equity of 1.12% and a net margin of 0.71%.
Pharming Group Stock Performance
PHGUF opened at $1.51 on Friday. The firm’s 50 day moving average is $1.77 and its 200-day moving average is $1.62. Pharming Group has a 52-week low of $0.79 and a 52-week high of $2.17. The company has a current ratio of 3.16, a quick ratio of 2.39 and a debt-to-equity ratio of 0.46.
About Pharming Group
Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.
Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.
Read More
- Five stocks we like better than Pharming Group
- A personal warning from Martin Weiss (Please read)
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Iran isn’t the real war
- This coin has everything going for it
- Only 500 people today…
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
